Interventions and Strategies to Improve Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Systematic Review of Systematic Reviews
Anticoagulation therapy is the fundamental approach for stroke prevention in atrial fibrillation (AF) patients. Numerous systematic reviews comparing anticoagulation strategies have been published. We aim to summarize the efficacy and safety evidence of these strategies in AF patients from previously published systematic reviews.
We searched PubMed, EMBASE and Cochrane library from inception to Feb 24th, 2017, to identify systematic reviews and meta-analyses of randomized controlled trials that assessed interventions or strategies to improve oral anticoagulant use in AF patients.
Thirty-four systematic reviews were eligible for inclusion but only 11 were included in the qualitative analyses, corresponding to 40 unique meta-analyses, as the remaining systematic reviews had overlapping primary studies. There was insufficient evidence to support the efficacy of genotype-guided dosing and pharmacist-managed anticoagulation clinics for stroke prevention in AF patients. Conversely, patient’s self-management and novel oral anticoagulants (NOACs), in general were superior to warfarin for preventing stroke and reducing mortality. All interventions showed comparable risk of major bleeding with warfarin.
Findings from this overview support the superiority of NOACs and patient’s self-management for preventing stroke in AF patients. However, uncertainties remain on the benefits of genotype-guided dosing and pharmacist-managed anticoagulation clinics due to poor quality evidence, and future research is warranted.
We are grateful for the help of Dr. Shaun Lee Wen Huey from School of Pharmacy, Monash University Malaysia for his invaluable advice and support in the preparation of this manuscript.
Compliance with Ethical Standards
This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
Siok Shen Ng, Nai Ming Lai, Surakit Nathisuwan and Nathorn Chaiyakunapruk have no conflict of interest to declare.
All authors have made substantial contributions to the research design, or the acquisition, analysis, or interpretation of data; and to drafting the paper or revising it critically; and that all authors have approved the submitted version.
- 9.Belley-Cote EP, Hanif H, D’Aragon F, Eikelboom JW, Anderson JL, Borgman M, et al. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thromb Haemost. 2015;114(4):768–77. https://doi.org/10.1160/th15-01-0071.CrossRefPubMedGoogle Scholar
- 11.Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381–91. https://doi.org/10.1161/circulationaha.112.115410.CrossRefPubMedGoogle Scholar
- 12.Garg J, Chaudhary R, Krishnamoorthy P, Palaniswamy C, Shah N, Bozorgnia B, et al. Safety and efficacy of oral factor-Xa inhibitors versus vitamin K antagonist in patients with non-valvular atrial fibrillation: meta-analysis of phase II and III randomized controlled trials. Int J Cardiol. 2016;218:235–9. https://doi.org/10.1016/j.ijcard.2016.05.059.CrossRefPubMedGoogle Scholar
- 13.Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;7. https://doi.org/10.1002/14651858.cd003839.pub3.
- 14.Katsanos AH, Mavridis D, Parissis J, Deftereos S, Frogoudaki A, Vrettou AR, et al. Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Ther Adv Neurol Disord. 2016;9(5):359–68. https://doi.org/10.1177/1756285616659411.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Morilla MA, Tumulak CD, Gulay CB, Dioquino CP, Morales DD. A meta-analysis on the efficacy of dabigatran versus warfarin among patients with atrial fibrillation. Philipp J Intern Med. 2012;50(4):1–4.Google Scholar
- 16.Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England). 2014;383(9921):955–62. https://doi.org/10.1016/s0140-6736(13)62343-0.CrossRefGoogle Scholar
- 18.Wells PS, Brown A, Jaffey J, McGahan L, Poon MC, Cimon K. Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis. Open Med Peer Rev Indep Open Access J. 2007;1(3):e131–46.Google Scholar
- 22.Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J. 2004;25(19):1734–40. https://doi.org/10.1016/j.ehj.2004.06.030.CrossRefPubMedGoogle Scholar
- 23.Providencia R, Grove EL, Husted S, Barra S, Boveda S, Morais J. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res. 2014;134(6):1253–64. https://doi.org/10.1016/j.thromres.2014.10.002.CrossRefPubMedGoogle Scholar
- 27.Sharma P, Scotland G, Cruickshank M, Tassie E, Fraser C, Burton C, et al. Is self-monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open. 2015;5(6):e007758. https://doi.org/10.1136/bmjopen-2015-007758.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.National Institute for Health and Care Excellence. Atrial fibrillation: management (CG180) [Internet]. NICE, London 2014. https://www.nice.org.uk/guidance/cg180.
- 29.White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239–45. https://doi.org/10.1001/archinte.167.3.239.CrossRefPubMedGoogle Scholar
- 33.Trusler M. Well-managed warfarin is superior to NOACs. Can Fam Phys. 2015;61(1):23–4.Google Scholar
- 34.Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F. Risk–benefit profile of direct-acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies. Drug Saf. 2016;39(12):1175–87. https://doi.org/10.1007/s40264-016-0464-3.CrossRefPubMedPubMedCentralGoogle Scholar